Liver Cancer (Locally Advanced or Metastatic) clinical trials

Study of two drugs for metastatic triple-negative breast cancer

This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.

Tele-rehab for rural men with metastatic prostate cancer

This trial tests a home-based exercise and support program delivered by phone or video for men with metastatic prostate cancer living in rural areas. The goal is to see if this approach improves quality of life and physical function compared to standard care.

Vaccine plus chemo for PD-L1 negative triple-negative breast cancer

This trial tests a cancer vaccine (STEMVAC) given alongside standard chemotherapy for people with a specific type of advanced triple-negative breast cancer that does not have the PD-L1 marker. The goal is to see if this combination can help the immune system fight the cancer more effectively.

Testing a new radioactive drug for HER2-positive advanced breast cancer

This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.

Plasma exchange plus targeted therapy for advanced bladder cancer

This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Lenvatinib, Nivolumab, and Chemo in Stomach Cancer with Ascites

This trial tests a combination of two drugs (lenvatinib and nivolumab) plus chemotherapy for people with advanced stomach cancer that has caused fluid buildup in the belly. The goal is to see if this combination can help shrink the cancer and reduce the fluid.

PQ203 for advanced solid tumors like triple-negative breast cancer

This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.

Tucatinib and trastuzumab for HER3-mutant breast cancer

This trial tests a combination of two targeted drugs (tucatinib and trastuzumab) for people with a specific gene change (HER3 mutation) in advanced breast cancer that has spread or cannot be removed by surgery. It may be an option if you have already had at least two previous treatments.

Study of BMS-986523 for advanced solid tumors with KRAS changes

This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.

MRI-guided radiation for liver cancers

This trial tests a precise MRI-guided radiation treatment for liver cancers, including liver cancer, bile duct cancer, or cancer that has spread to the liver. The goal is to target tumors more accurately while protecting healthy tissue.

Spiritual care help for advanced cancer patients

This study tests a program where a chaplain and doctor work together to support your spiritual beliefs about medical care. The goal is to see if it helps patients with advanced cancer feel more at peace with their treatment choices.

VSV-02 for advanced solid tumors that need new options

This trial tests an experimental virus therapy called VSV-02 for people with advanced solid tumors that have not responded to standard treatments. The treatment is given directly into a tumor, aiming to attack cancer from the inside.

PTEN and Organ-Specific microRNAs in Breast Cancer

This trial looks at specific molecules (PTEN and microRNAs) in the blood to see if they help doctors understand how breast cancer spreads. If you have breast cancer (whether it has spread or not) or are healthy, you might be eligible.

Study samples from metastatic triple-negative breast cancer

This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.

Testing new cancer drugs for advanced prostate cancer

This study tests new anti-cancer drugs for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to find treatments that work when standard drugs no longer help.

Study of setidegrasib with chemo for pancreatic cancer

This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.

Testing a new drug for advanced cervical cancer after standard treatments

This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.

Combination targeted drug and immunotherapy for recurrent gynecologic cancers

This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.

Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation

This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.

LB-100 plus Atezolizumab for metastatic colorectal cancer

This trial tests a new two-drug combination (LB-100 plus atezolizumab) for people with metastatic colorectal cancer that hasn't responded to standard treatment. The goal is to see if the combination can help shrink or slow the cancer.

New drug plus standard chemo for spread colorectal cancer

This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.

Brain scan surveillance in HER2-positive metastatic breast cancer

This study tests whether regular brain scans (surveillance) help spot brain metastases early in people with HER2-positive breast cancer that has spread to other parts of the body. Participation involves being randomly assigned to either routine brain scans or no extra scans to see which approach is better.

Toripalimab Plus Chemotherapy for Advanced HER2-Negative Breast Cancer

This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.